Merck and Daiichi Sankyo, which were seeking approval of patritumab deruxtecan for adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer previously treated with two or ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition. IHH ...

"Daiichi Sankyo and AstraZeneca’s Enhertu shows OS improvements in Phase III trial" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effe ...

Daiichi Sankyo Company, Ltd (TSE: 4568) announced today that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-a ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

DAIICHI SANKYO will report earnings from the last quarter on January 31. Analysts on Wall Street expect DAIICHI SANKYO will release earnings per share of ¥16.98.

Japan's health ministry said on Friday it agreed to buy 1.4 million doses of Daiichi Sankyo's updated COVID-19 vaccine.

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

While Daiichi Sankyo has been focusing on a stable of antibody-drug conjugates, the Japanese company has won a global first in an area that Pfizer is also targeting. | While Daiichi Sankyo has ...

U.S. drugmaker Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using its drug technology.

Partners AstraZeneca and Daiichi Sankyo now have clinical data showing that their HER2-targeting drug, Enhertu, can address so-called “HER2-low” breast cancers.